VTRS Viatris
Shrinking generics giant; GAAP losses mask a levered cash machine, fairly to modestly overpriced today.
The story
Viatris is a scale generics and off-patent branded drug company built from the Mylan/Upjohn merger. Its moat is manufacturing scale, global distribution and a broad portfolio, not pricing power. Revenue is slowly shrinking as legacy brands erode and divestitures roll off, and GAAP losses come mostly from impairments and non-cash amortization of acquired intangibles. Underneath, it is a mature, levered cash generator whose main job is to pay down debt and return cash while stabilizing the top line through a modest pipeline.
Growth, reinvestment, risk and horizon are unchanged because the facts have not changed: there is mild erosion, capex is light and the beta is at the industry anchor. I raised the target margin from 17% to 20% (+18% relative) after reconciling with the market. My prior value was less than half the price. Reported margins are depressed by roughly 15% of sales in acquired-intangible amortization and one-off impairments, both of which run off, while sustainable cash EBIT for a scale generics player sits near 20%.
Value drivers
| Revenue growth (Y1) | -1.5% |
| Terminal growth | 0.5% |
| Forecast horizon | 6y |
| Target operating margin | 20.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.40 |
| Beta | 0.95 |
| Failure probability | 5.0% |
| Cost of capital (WACC) | 7.6% |
| Terminal WACC | 7.8% |
Valuation bridge
| PV of explicit FCFF | 8.34B |
| PV of terminal value | 18.81B |
| Equity value | 13.36B |
| ÷ shares → per share | $11.63 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 14.52B | -1.5% | 5.8% | 670.00M | 0 | 670.00M | 622.51M |
| 2 | 14.36B | -1.1% | 12.9% | 1.47B | 0 | 1.47B | 1.27B |
| 3 | 14.26B | -0.7% | 20.0% | 2.25B | 0 | 2.25B | 1.81B |
| 4 | 14.21B | -0.3% | 20.0% | 2.25B | 0 | 2.25B | 1.67B |
| 5 | 14.23B | 0.1% | 20.0% | 2.25B | 10.15M | 2.24B | 1.55B |
| 6 | 14.30B | 0.5% | 20.0% | 2.26B | 50.81M | 2.21B | 1.42B |
Key risks
- FDA compliance problems (e.g., the Indore facility) disrupting supply and US generics revenue
- Faster price erosion in US generics and in legacy brands like Lipitor and Norvasc in China and emerging markets
- About $13B of net debt magnifies any cash-flow shortfall, and more impairments may point to overpaid assets
Catalysts
- Continued deleveraging and buybacks shrinking the share count
- Pipeline approvals (e.g., novel and complex injectables) that halt revenue decline